5-chloro-1-azidopentane | 1026864-25-4

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 5-chloro-1-azidopentane
• 英文别名: 1-Azido-5-chloropentane
• CAS: 1026864-25-4
• 化学式: C₅H₁₀ClN₃
• 分子量: 147.608
• InChiKey: XWVZQJBZFOVNCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  14.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-1-azidopentane 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以75%的产率得到1-chloro-5-aminopentane hydrochloride
  参考文献：
  名称：

  Aliphatic amino azides as key building blocks for efficient polyamine syntheses

  摘要：

  New routes to open-chain polyamines have been developed using aliphatic amino azides as common precursors for the construction of the carbon-nitrogen framework. These alpha,omega-diaminoalkane synthetic equivalents were combined with (omega-halogenoalkyl)dichloroboranes to extend the polyamine chain from the azido moiety. An extension from the free amino group can also be achieved via a Michael type addition with acrylonitrile or a reductive amination with a gamma-azido ketone. Further transformations led to a large variety of regioselectively C- or (and) N-substituted polyamines.

  DOI：

  10.1021/jo00066a028
• 作为产物：
  描述：

  1-氯-5-碘戊烷 在 thallium(I) azide 作用下， 以 乙腈 为溶剂， 反应 72.0h， 生成 5-chloro-1-azidopentane
  参考文献：
  名称：

  Synthesis of Fully Aliphatic Aziridines with a Macrocyclic Tetracarbene Iron Catalyst

  摘要：

  A second-generation aziridination catalyst supported by a borate-based dianionic macrocyclic tetracarbene ligand has been synthesized. The new macrocyclic tetracarbene iron(II) complex catalyzed the aziridination of alkyl azides and aliphatic alkenes showcasing the first fully aliphatic version of this C-2 + N-1 reaction. High isolated yields were obtained when no functional groups were present on the organic azides and alkenes, while modest yields were achieved when nonprotic functional groups were included. Even multiple functional groups can be added to the azide and alkene fragments to produce the most complex aziridines yet synthesized by this C-2 + N-1 catalytic reaction. The catalyst generated higher yields for aziridination with aryl azides and alkenes than the previously reported catalyst, [((TCPh)-T-Me,Et)Fe(NCCH3)(2)](PF6)(2). The contrast is particularly apparent with functionalized aryl azides where the second-generation catalyst now provides practical yields for synthetic chemistry. Finally, catalytic intramolecular aziridination was investigated since many natural products with aziridines feature bicyclic tertiary aziridines. For five- and six-membered rings, the bicyclic aziridines were formed catalytically, in contrast to previously studied catalyzed and uncatalyzed reactions.

  DOI：

  10.1021/acs.organomet.6b00066

文献信息

• MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS
  申请人：Zarling David A.

  公开号：US20110059922A1

  公开（公告）日：2011-03-10

  The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.

  披露的发明包括使用含有脂溶性阳离子基团与亚硝酰基或羟胺抗氧化基团相连的药用盐来治疗癌症和相关的新生物病变，特别是前列腺癌的方法。
• 4-Substituted alkyl carbapenem antibiotics
  申请人：Bristol-Myers Squibb Company

  公开号：EP0433759A1

  公开（公告）日：1991-06-26

  Compounds of the formula wherein R1 is hydrogen, C1-2 alkyl, -CH20H, -CH2NH2, A is an unsubstituted or hydroxy-substituted straight or branched C, -, 10 alkylene group or a straight or branched C1-10 alkylene group having an intervening heteroatom selected from oxygen, sulfur and nitrogen; R2 is hydroxy, halogen, C1-4 alkoxy, nitrile, azido, a quaternary ammonio group, -NRSR6, azetidinyl, or a 5- or 6-membered heterocyclic group selected from heteroaromatic and heteroalicyclic joined through a carbon atom thereof; B is a straight or branched C, -6 alkylene group or a direct bond when R3 is joined to the sulfur atom through a carbon atom thereof; R3 is a residue of an organic group; R4 is hydrogen, a removable carboxy-protecting group or a physiologically hydrolyzable ester group; R5 and R6 each are independently hydrogen, C1-6 alkyl, C1-4 alkoxy, hydroxyethyl, azidoethyl, aminoethyl, and when R5 is hydrogen or C, -a alkyl, R6 is hydroxy, C1-4 alkoxy, amino, C1-4 alkylamino, di(Ci-4.)alkylamino, substituted C1-4 alkyl wherein said alkyl substituent is selected from hydroxy, azido, amino, guanidino, nitrile, carboxy, formimidoyl and phenyl, or an acyl residue of an amino acid or peptide; or R5 and R6, taken together with the nitrogen atom to which they are attached, is an unsubstituted or substituted heterocyclic ring having 1 to 2 ring members and having up to four heteroatoms in each ring independently selected from oxygen, nitrogen and sulfur, wherein said substituent is selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, trifluoromethyl, hydroxy, halogen, amino, nitrile, carboxy, carbamido, carbamoyl, C, -4 alkylamino and amino (C1-4) alkyl; W is a direct bond, oxygen, sulfur or NR'°; Y is oxygen or NR10; Z is hydrogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, -NR7R8, amino(C1-4)alkyl, azido(C1-4)alkyl or hydroxy (C1-4)alkyl; R7 and R8 each are independently hydrogen, C1-4 alkyl or alkanoyl; and R10 is hydrogen, C1-4 alkyl, C1-4 alkylamino or di(C1-4)alkylamino; or a non-toxic pharmaceutically acceptable salt thereof, are novel antimicrobial agents which are useful in the treatment of infectious disease in humans and other animals. Novel intermediates and processes for their preparation are also disclosed.

  式中的化合物 其中 R1 为氢、C1-2 烷基、-CH20H、-CH2NH2、 A 是未取代的或羟基取代的直链或支链 C,-,10-亚烷基，或具有选自氧、硫和氮的杂原子的直链或支链 C1-10 亚烷基； R2 是羟基、卤素、C1-4 烷氧基、腈、叠氮、季铵基、-NRSR6、 氮杂环丁基，或通过一个碳原子连接的 5 或 6 元杂环基团，这些杂环基团选自杂芳族和杂脂环； B 是直链或支链 C, -6 亚烷基，或当 R3 通过其碳原子与硫原子相连时的直接键； R3 是有机基团的残基； R4 是氢、可去除的羧基保护基团或生理上可水解的酯基； R5和R6各自独立地是氢、C1-6烷基、C1-4烷氧基、羟乙基、叠氮乙基、氨基乙基，当R5是氢或C, -a烷基时，R6是羟基、C1-4烷氧基、氨基、C1-4烷基氨基、二(Ci-4.当 R5 为氢或 C-a烷基时，R6 为羟基、C1-4烷氧基、氨基、C1-4烷基氨基、二(Ci-4. )烷基氨基、取代的 C1-4 烷基，其中所述烷基取代基选自羟基、叠氮基、氨基、胍基、腈基、羧基、甲酰亚胺基和苯基，或氨基酸或肽的酰基残基；或 R5 和 R6，连同它们所连接的氮原子，是一个未取代或取代的杂环，具有 1 至 2 个环成员，且每个环中具有最多 4 个独立选自氧、氮和硫的杂原子，其中所述取代基选自由 C1-4 烷基、C1-4 烷氧基、三氟甲基、羟基、卤素、氨基、腈、羧基、氨基甲酰基、氨基甲酰基、C, -4 烷基氨基和氨基（C1-4）烷基组成的组；W 是直接键、氧、硫或 NR'°； Y 是氧或 NR10 Z 是氢、羟基、C1-4 烷基、C1-4 烷氧基、-NR7R8、氨基（C1-4）烷基、叠氮（C1-4）烷基或羟基（C1-4）烷基； R7 和 R8 各自独立地为氢、C1-4 烷基或烷酰基；以及 R10 是氢、C1-4 烷基、C1-4 烷基氨基或二(C1-4)烷基氨基； 或其无毒药学上可接受的盐，是新型抗菌剂，可用于治疗人类和其他动物的传染性疾病。此外，还公开了新型中间体及其制备工艺。
• INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION
  申请人：Marcaurelle Lisa A.

  公开号：US20100280238A1

  公开（公告）日：2010-11-04

  The Huisgen 1,3-dipolar cycloaddition is a ‘click’ reaction that results from the ligation of azides and alkynes to give a triazole moiety. This reaction has been shown to be effective in the formation of a variety of macrocyclic rings. A key point of interest is the regioselectivity and specificity of the cycloaddition. Disclosed herein are specific, selective, and high-yielding methods of azide-alkyne macrocyclization to form 1,4- and 1,5-triazoles and libraries thereof.
• THIOLACTONE ANTIBIOTICS
  申请人：Tonge Peter

  公开号：US20140113941A1

  公开（公告）日：2014-04-24

  This invention provides a compound having the structure wherein R 1 is H, wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is wherein m is an integer from 0 to 8; R 3 is an amino, alkyl, aryl, heteroaryl, diol, piperazine, morpholine, piperidine, triazole, azide or biphenyl, each with or without substitution, branched or unbranched, or and R 4 is alkyl, aryl, or heteroaryl, each with or without substitution, branched or unbranched, R 2 is H, CH 3 , or alkyl, aryl, heteroaryl, pyrrole, diazole, or triazole, each with or without substitution, branched or unbranched, or wherein n and q are independently an integer from 0 to 8; A is absent or present and when present is and R 6 is azide, methoxy, trifluoromethyl, biphenyl, substituted phenyl, substituted triazole, or alkyl, aryl or heteroaryl, with or without substitution, branched or unbranched, when R 1 is H then R 2 is other than H or CH 3 , and when R 2 is H or CH 3 then R 1 is other than H, or a pharmaceutically acceptable salt thereof.
• US4272437A
  申请人：——

  公开号：US4272437A

  公开（公告）日：1981-06-09